Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials - PubMed
4 hours ago
- #GLP-1 receptor agonists
- #obesity
- #lean body mass
- The study compares lean mass changes between incretin-based therapies (GLP-1 receptor agonists and dual GLP-1/GIP agonists) and intensive lifestyle interventions in adults with overweight or obesity.
- Lean mass constituted 25%-39% of total weight lost with incretin agonists: semaglutide (35.2%), tirzepatide (25.4%), and liraglutide (26.8%).
- Lifestyle interventions showed comparable proportional lean mass loss (26.2%), while lifestyle plus resistance training demonstrated the most favourable profile (17.5%).
- The proportion of weight lost as lean mass is broadly comparable between incretin-based pharmacotherapy and lifestyle interventions.
- Muscle mass can be significantly preserved by integrating resistance training, adequate protein intake, and body composition monitoring into weight-loss treatment programs.